Co-Authors
This is a "connection" page, showing publications co-authored by Lu Lu and Shuai Xia.
Connection Strength
6.565
-
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. Signal Transduct Target Ther. 2021 07 29; 6(1):288.
Score: 0.959
-
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020 Apr; 30(4):343-355.
Score: 0.874
-
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020 07; 17(7):765-767.
Score: 0.867
-
A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019 04; 5(4):eaav4580.
Score: 0.817
-
Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. Viruses. 2019 01 14; 11(1).
Score: 0.804
-
Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020 08; 17(8):894.
Score: 0.224
-
The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct Target Ther. 2020 06 12; 5(1):92.
Score: 0.222
-
RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020 04 07.
Score: 0.219
-
Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. Virol Sin. 2020 06; 35(3):340-343.
Score: 0.219
-
Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains. Int J Mol Sci. 2018 Feb 06; 19(2).
Score: 0.188
-
Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. Antimicrob Agents Chemother. 2017 04; 61(4).
Score: 0.177
-
Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors. J Virol. 2017 Jan 01; 91(1).
Score: 0.174
-
[Development of peptidic MERS-CoV entry inhibitors]. Yao Xue Xue Bao. 2015 Dec; 50(12):1513-9.
Score: 0.162
-
Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). Emerg Microbes Infect. 2015 Jun 17; 4:e37.
Score: 0.157
-
Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014 Dec 19; 194:200-10.
Score: 0.150
-
Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation. Signal Transduct Target Ther. 2021 08 26; 6(1):318.
Score: 0.060
-
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020 11 27; 5(1):282.
Score: 0.057
-
Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. Proc Natl Acad Sci U S A. 2020 11 03; 117(44):27141-27147.
Score: 0.057
-
Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. Int J Mol Sci. 2020 May 28; 21(11).
Score: 0.055
-
A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Cell Host Microbe. 2017 Oct 11; 22(4):471-483.e5.
Score: 0.046
-
Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. J Infect Dis. 2015 Dec 15; 212(12):1894-903.
Score: 0.039
-
Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother. 2015 Jan; 59(1):742-4.
Score: 0.037